Takeda Pharmaceutical Co Ltd (HAM:TKD)
€ 25.5 -0.16 (-0.62%) Market Cap: 41.10 Bil Enterprise Value: 67.01 Bil PE Ratio: 22.79 PB Ratio: 0.95 GF Score: 75/100

Takeda Pharmaceutical Co Ltd World Conference on Lung Cancer (WCLC) Investor Call Transcript

Jan 29, 2021 / 10:00PM GMT
Release Date Price: €29.02 (-0.70%)
Operator

And now, please welcome Director Investor Relations, Elizabeth Borgeson.

Elizabeth Borgeson;Teresa Bitetti
Takeda Pharmaceutical Company Limited -

Thanks. Good evening, everyone. Thanks for joining us on our mobo call today. This is Elizabeth Borgeson. I'm a part of the Takeda Investor Relations team working out in New York City.

Before we get started, let me cover the safe harbor statement on the next slide. I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20-F and in our other SEC filings. Please also refer to the important notice on Page 2 of the presentation.

Next slide, please. All right. And without further ado, I'd like to introduce Teresa Bitetti. Teresa is the President of our Global Oncology Business Unit. Take it away, Teresa.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot